Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Women's Health | 14 | 2021 | 173 | 1.660 |
Why?
|
| Metabolic Syndrome | 6 | 2020 | 56 | 1.580 |
Why?
|
| Menopause | 9 | 2021 | 101 | 1.400 |
Why?
|
| Adiposity | 8 | 2018 | 43 | 1.390 |
Why?
|
| Intra-Abdominal Fat | 6 | 2021 | 40 | 1.210 |
Why?
|
| Obesity | 6 | 2018 | 297 | 1.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2015 | 160 | 1.040 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 307 | 0.980 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 121 | 0.850 |
Why?
|
| Ecosystem | 1 | 2023 | 24 | 0.840 |
Why?
|
| Middle Aged | 36 | 2021 | 8772 | 0.830 |
Why?
|
| Thrombosis | 2 | 2014 | 51 | 0.790 |
Why?
|
| Obesity, Abdominal | 4 | 2015 | 19 | 0.760 |
Why?
|
| Atrial Fibrillation | 2 | 2014 | 98 | 0.740 |
Why?
|
| Female | 43 | 2021 | 14734 | 0.720 |
Why?
|
| Adrenal Gland Diseases | 2 | 2012 | 3 | 0.690 |
Why?
|
| Humans | 47 | 2023 | 25967 | 0.630 |
Why?
|
| Abdominal Fat | 3 | 2021 | 9 | 0.620 |
Why?
|
| Diet Therapy | 1 | 2018 | 10 | 0.600 |
Why?
|
| Risk Factors | 20 | 2021 | 2237 | 0.590 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 20 | 0.580 |
Why?
|
| Atherosclerosis | 3 | 2021 | 52 | 0.570 |
Why?
|
| Exercise Therapy | 1 | 2018 | 90 | 0.560 |
Why?
|
| Behavior Therapy | 1 | 2018 | 86 | 0.560 |
Why?
|
| Adult | 22 | 2021 | 7662 | 0.550 |
Why?
|
| United States | 15 | 2021 | 1989 | 0.540 |
Why?
|
| Hydrocortisone | 3 | 2012 | 38 | 0.540 |
Why?
|
| Testosterone | 2 | 2014 | 28 | 0.540 |
Why?
|
| Waist-Height Ratio | 1 | 2016 | 5 | 0.530 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 7 | 0.520 |
Why?
|
| Mass Screening | 1 | 2016 | 170 | 0.470 |
Why?
|
| Cognition Disorders | 2 | 2020 | 957 | 0.470 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 31 | 0.430 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 9 | 0.410 |
Why?
|
| Prevalence | 4 | 2016 | 433 | 0.400 |
Why?
|
| Adrenal Cortex Function Tests | 1 | 2012 | 1 | 0.400 |
Why?
|
| Hemodynamics | 1 | 2012 | 62 | 0.390 |
Why?
|
| Liver Cirrhosis | 1 | 2012 | 44 | 0.380 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2009 | 6 | 0.380 |
Why?
|
| Postmenopause | 6 | 2019 | 57 | 0.380 |
Why?
|
| Lipoproteins, HDL | 3 | 2014 | 23 | 0.370 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2009 | 2 | 0.370 |
Why?
|
| Biomarkers | 5 | 2020 | 544 | 0.360 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2021 | 17 | 0.360 |
Why?
|
| Perimenopause | 3 | 2021 | 14 | 0.350 |
Why?
|
| Longitudinal Studies | 9 | 2020 | 1333 | 0.350 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 1757 | 0.340 |
Why?
|
| Diastole | 1 | 2010 | 29 | 0.330 |
Why?
|
| Absorptiometry, Photon | 3 | 2015 | 83 | 0.330 |
Why?
|
| Blood Glucose | 5 | 2020 | 102 | 0.330 |
Why?
|
| Adrenal Insufficiency | 1 | 2009 | 6 | 0.330 |
Why?
|
| Cardiomyopathies | 1 | 2010 | 25 | 0.320 |
Why?
|
| Vitamin D | 1 | 2010 | 31 | 0.320 |
Why?
|
| Reproducibility of Results | 4 | 2014 | 649 | 0.310 |
Why?
|
| Hypertension | 4 | 2021 | 181 | 0.300 |
Why?
|
| Algorithms | 3 | 2023 | 345 | 0.300 |
Why?
|
| Pituitary Diseases | 1 | 2008 | 3 | 0.300 |
Why?
|
| Hypothalamic Diseases | 1 | 2008 | 8 | 0.300 |
Why?
|
| Depression | 3 | 2018 | 412 | 0.280 |
Why?
|
| Socioeconomic Factors | 4 | 2023 | 294 | 0.280 |
Why?
|
| Prospective Studies | 6 | 2020 | 1701 | 0.280 |
Why?
|
| Body Mass Index | 5 | 2018 | 449 | 0.280 |
Why?
|
| Population Surveillance | 2 | 2020 | 112 | 0.270 |
Why?
|
| Cohort Studies | 7 | 2020 | 1806 | 0.260 |
Why?
|
| Exercise | 3 | 2018 | 434 | 0.260 |
Why?
|
| Male | 13 | 2020 | 14277 | 0.260 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 473 | 0.260 |
Why?
|
| Risk Assessment | 3 | 2020 | 603 | 0.260 |
Why?
|
| Prognosis | 3 | 2020 | 784 | 0.250 |
Why?
|
| Ketone Bodies | 1 | 2005 | 4 | 0.240 |
Why?
|
| Incidence | 5 | 2020 | 729 | 0.230 |
Why?
|
| ROC Curve | 3 | 2009 | 141 | 0.230 |
Why?
|
| Insulin | 2 | 2011 | 84 | 0.220 |
Why?
|
| Diet | 2 | 2019 | 197 | 0.220 |
Why?
|
| Economic Development | 1 | 2023 | 3 | 0.220 |
Why?
|
| Estradiol | 4 | 2021 | 53 | 0.220 |
Why?
|
| Developing Countries | 1 | 2023 | 13 | 0.220 |
Why?
|
| Chicago | 5 | 2014 | 898 | 0.210 |
Why?
|
| Pregnanediol | 2 | 2021 | 7 | 0.210 |
Why?
|
| Luteinizing Hormone | 2 | 2021 | 12 | 0.210 |
Why?
|
| Pharmacoepidemiology | 2 | 2020 | 4 | 0.210 |
Why?
|
| Life Style | 2 | 2018 | 177 | 0.210 |
Why?
|
| Atrial Appendage | 2 | 2014 | 27 | 0.210 |
Why?
|
| Energy Intake | 3 | 2019 | 77 | 0.200 |
Why?
|
| Hypoglycemic Agents | 1 | 2003 | 36 | 0.200 |
Why?
|
| Aged | 11 | 2020 | 8732 | 0.200 |
Why?
|
| Energy Metabolism | 2 | 2018 | 47 | 0.200 |
Why?
|
| Waist Circumference | 4 | 2016 | 35 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 263 | 0.190 |
Why?
|
| Stroke Volume | 2 | 2014 | 43 | 0.190 |
Why?
|
| Hyperglycemia | 2 | 2020 | 28 | 0.190 |
Why?
|
| Menstrual Cycle | 2 | 2021 | 19 | 0.180 |
Why?
|
| Progesterone | 1 | 2021 | 20 | 0.180 |
Why?
|
| Carotid Artery Diseases | 1 | 2021 | 13 | 0.180 |
Why?
|
| Cosyntropin | 2 | 2012 | 3 | 0.170 |
Why?
|
| Multimorbidity | 1 | 2020 | 6 | 0.170 |
Why?
|
| Insulin Resistance | 4 | 2011 | 50 | 0.170 |
Why?
|
| Cholesterol, HDL | 3 | 2011 | 26 | 0.160 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 93 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 50 | 0.160 |
Why?
|
| Cerebral Hemorrhage | 1 | 2020 | 106 | 0.160 |
Why?
|
| Seasons | 1 | 2019 | 22 | 0.160 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 46 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 90 | 0.150 |
Why?
|
| Appetite | 1 | 2018 | 4 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2020 | 404 | 0.150 |
Why?
|
| Weight Gain | 1 | 2018 | 59 | 0.150 |
Why?
|
| Fractures, Bone | 1 | 2019 | 73 | 0.150 |
Why?
|
| Body Weight | 1 | 2018 | 132 | 0.140 |
Why?
|
| Time Factors | 4 | 2020 | 1391 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 366 | 0.140 |
Why?
|
| Weight Loss | 1 | 2018 | 122 | 0.140 |
Why?
|
| Hormones | 1 | 2017 | 15 | 0.140 |
Why?
|
| Depressive Disorder | 1 | 2018 | 172 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 118 | 0.140 |
Why?
|
| Social Support | 1 | 2018 | 190 | 0.140 |
Why?
|
| Beverages | 1 | 2016 | 12 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2009 | 851 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 466 | 0.130 |
Why?
|
| Child | 3 | 2009 | 1217 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2014 | 3358 | 0.130 |
Why?
|
| Climacteric | 1 | 2015 | 4 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 648 | 0.120 |
Why?
|
| Estrogens | 1 | 2015 | 26 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2015 | 33 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 19 | 0.120 |
Why?
|
| Immunoassay | 1 | 2015 | 37 | 0.120 |
Why?
|
| Age Factors | 3 | 2020 | 757 | 0.120 |
Why?
|
| Carbonated Beverages | 1 | 2014 | 2 | 0.120 |
Why?
|
| Research Report | 1 | 2014 | 5 | 0.120 |
Why?
|
| Sweetening Agents | 1 | 2014 | 5 | 0.120 |
Why?
|
| Waist-Hip Ratio | 1 | 2014 | 13 | 0.120 |
Why?
|
| Birth Weight | 1 | 2015 | 38 | 0.110 |
Why?
|
| Meals | 1 | 2014 | 10 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2015 | 33 | 0.110 |
Why?
|
| Illinois | 2 | 2013 | 235 | 0.110 |
Why?
|
| Hyperandrogenism | 1 | 2014 | 2 | 0.110 |
Why?
|
| Oligomenorrhea | 1 | 2014 | 2 | 0.110 |
Why?
|
| Self Report | 3 | 2020 | 217 | 0.110 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2014 | 32 | 0.110 |
Why?
|
| Personal Satisfaction | 1 | 2014 | 43 | 0.110 |
Why?
|
| Body Image | 1 | 2014 | 27 | 0.110 |
Why?
|
| Employment | 1 | 2013 | 40 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2013 | 11 | 0.100 |
Why?
|
| Motor Activity | 2 | 2018 | 317 | 0.100 |
Why?
|
| Body Fat Distribution | 1 | 2012 | 12 | 0.100 |
Why?
|
| Blood Pressure | 4 | 2019 | 184 | 0.100 |
Why?
|
| Logistic Models | 3 | 2019 | 391 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 174 | 0.090 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 990 | 0.090 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 1150 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2012 | 168 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 332 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2013 | 207 | 0.090 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2011 | 2 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 402 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 4641 | 0.080 |
Why?
|
| Infant | 2 | 2009 | 495 | 0.080 |
Why?
|
| Calcifediol | 1 | 2010 | 2 | 0.080 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2010 | 2 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 34 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2009 | 597 | 0.080 |
Why?
|
| Pericardium | 1 | 2010 | 20 | 0.080 |
Why?
|
| Particle Size | 1 | 2010 | 48 | 0.080 |
Why?
|
| Metyrapone | 1 | 2009 | 1 | 0.080 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 13 | 0.080 |
Why?
|
| Reference Standards | 1 | 2009 | 22 | 0.080 |
Why?
|
| Antimetabolites | 1 | 2009 | 12 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 72 | 0.080 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2021 | 22 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 251 | 0.080 |
Why?
|
| Hospitals, Public | 1 | 2009 | 27 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 868 | 0.080 |
Why?
|
| Health Behavior | 1 | 2010 | 157 | 0.080 |
Why?
|
| Fasting | 1 | 2008 | 20 | 0.070 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2008 | 22 | 0.070 |
Why?
|
| Urban Population | 1 | 2009 | 149 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2008 | 63 | 0.070 |
Why?
|
| Hypercalcemia | 1 | 2007 | 7 | 0.070 |
Why?
|
| Burns | 1 | 2007 | 18 | 0.070 |
Why?
|
| Carotid Arteries | 2 | 2021 | 14 | 0.070 |
Why?
|
| Adolescent | 2 | 2009 | 2099 | 0.060 |
Why?
|
| Linear Models | 2 | 2018 | 240 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 128 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2007 | 248 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 158 | 0.060 |
Why?
|
| Lamin Type A | 1 | 2004 | 2 | 0.060 |
Why?
|
| Lipodystrophy | 1 | 2004 | 1 | 0.060 |
Why?
|
| Acyltransferases | 1 | 2004 | 4 | 0.060 |
Why?
|
| GTP-Binding Protein gamma Subunits | 1 | 2004 | 3 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 54 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2015 | 268 | 0.050 |
Why?
|
| Young Adult | 1 | 2009 | 1941 | 0.050 |
Why?
|
| Gluconeogenesis | 1 | 2003 | 3 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2003 | 3 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 18 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2003 | 38 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2014 | 296 | 0.050 |
Why?
|
| Triglycerides | 2 | 2014 | 56 | 0.050 |
Why?
|
| Liver | 1 | 2003 | 143 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2015 | 1107 | 0.050 |
Why?
|
| Patient Selection | 1 | 2003 | 190 | 0.050 |
Why?
|
| Ankle Brachial Index | 1 | 2021 | 2 | 0.050 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 4 | 0.050 |
Why?
|
| Cognition | 1 | 2009 | 1250 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 252 | 0.050 |
Why?
|
| Vasomotor System | 1 | 2021 | 3 | 0.040 |
Why?
|
| Disease Progression | 1 | 2003 | 655 | 0.040 |
Why?
|
| Affect | 1 | 2021 | 59 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 51 | 0.040 |
Why?
|
| Hypertriglyceridemia | 2 | 2014 | 20 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2019 | 26 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 36 | 0.040 |
Why?
|
| Healthy Aging | 1 | 2018 | 14 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2018 | 55 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2019 | 73 | 0.040 |
Why?
|
| Hospitalization | 1 | 2020 | 301 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2018 | 252 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2019 | 108 | 0.040 |
Why?
|
| Sleep | 1 | 2020 | 288 | 0.040 |
Why?
|
| Estrone | 1 | 2017 | 8 | 0.030 |
Why?
|
| Corpus Luteum | 1 | 2017 | 5 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 268 | 0.030 |
Why?
|
| Premenopause | 1 | 2017 | 11 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 339 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 22 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 19 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 64 | 0.030 |
Why?
|
| Androgens | 1 | 2014 | 7 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 326 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 571 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 128 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2011 | 11 | 0.020 |
Why?
|
| Stroke | 1 | 2014 | 259 | 0.020 |
Why?
|
| Nutrition Policy | 1 | 2010 | 9 | 0.020 |
Why?
|
| France | 1 | 2010 | 13 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 40 | 0.020 |
Why?
|
| Fruit | 1 | 2010 | 26 | 0.020 |
Why?
|
| Vegetables | 1 | 2010 | 25 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2010 | 37 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2010 | 39 | 0.020 |
Why?
|
| Biological Availability | 1 | 2009 | 16 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2009 | 16 | 0.020 |
Why?
|
| Aging | 1 | 2018 | 1483 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 210 | 0.020 |
Why?
|
| Albumins | 1 | 2007 | 18 | 0.020 |
Why?
|
| Knowledge | 1 | 2007 | 15 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 29 | 0.020 |
Why?
|
| Lipids | 1 | 2007 | 48 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 3399 | 0.020 |
Why?
|
| Length of Stay | 1 | 2007 | 307 | 0.010 |
Why?
|
| Calcium | 1 | 2007 | 361 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2004 | 6 | 0.010 |
Why?
|
| Consanguinity | 1 | 2004 | 3 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2004 | 7 | 0.010 |
Why?
|
| 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2004 | 1 | 0.010 |
Why?
|
| Hyperinsulinism | 1 | 2004 | 4 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2004 | 4 | 0.010 |
Why?
|
| RNA Splice Sites | 1 | 2004 | 2 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 35 | 0.010 |
Why?
|
| Exons | 1 | 2004 | 33 | 0.010 |
Why?
|
| Homozygote | 1 | 2004 | 18 | 0.010 |
Why?
|
| Haplotypes | 1 | 2004 | 55 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 204 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 290 | 0.010 |
Why?
|